Abstract
Gamma delta (γδ) Τ cells are non-conventional T lymphocyte effectors that can interact with and eradicate tumour cells. Several data demonstrate that these T cells, which are implicated in the first line of defence against pathogens, have anti-tumour activity against many cancers and suggest that γδ Τ cell-mediated immunotherapy is feasible and might induce objective tumour responses. Due to the importance of γδ Τ lymphocytes in the induction and control of immunity, a complete understanding of their biology is crucial for the development of a potent cancer immunotherapy. This review discusses recent advances in γδ Τ basic research and data from clinical trials on the use of γδ Τ cells in the treatment of different cancers. It analyses how this knowledge might be applied to develop new strategies for the clinical manipulation and the potentiation of γδ Τ lymphocyte activity in cancer immunotherapy.
| Original language | English |
|---|---|
| Pages (from-to) | 123-132 |
| Number of pages | 10 |
| Journal | British Journal of Haematology |
| Volume | 160 |
| Issue number | 2 |
| DOIs | |
| State | Published - Jan 2013 |
| Externally published | Yes |
Keywords
- Cancer
- Gamma delta T lymphocytes
- Haematological oncology
- Immunotherapy
- Monoclonal antibodies